Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: A large retrospective study on 240 patients enrolled in the French Named-Patient Program

Haematologica

Volumn 101, Issue 4, 2016, Pages 466-473

  Perrot, Aurore ^a   Monjanel, Hélène ^b   Bouabdallah, Réda ^c   Quittet, Philippe ^d   Sarkozy, Clémentine ^e   Bernard, Marc ^f   Stamatoullas, Aspasia ^g   Borel, Cécile ^h   Bouabdallah, Krimo ⁱ   Nicolas Virelizier, Emmanuelle ^j   Fournier, Marion ^k   Morschhauser, Franck ^l   Brice, Pauline ^b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d LAPEYRONIE HOSPITAL   (France)

^e UNIVERSITÉ LYON 1   (France)

^f PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^g CENTRE HENRI BECQUEREL   (France)

^h Institut Universitaire du Cancer   (France)

ⁱ HAUT LÉVÊQUE HOSPITAL   (France)

^j CENTRE LÉON BÉRARD   (France)

^k CENTRE HOSPITALIER LYON SUD   (France)

^l Univ Lille   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ANEMIA; ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLOW UP; HISTOLOGY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; VOMITING; ADOLESCENT; AGED; CANCER STAGING; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG RESISTANCE; FRANCE; GENE EXPRESSION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; MULTICENTER STUDY; NAUSEA; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; RECURRENT DISEASE; REMISSION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD30; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FRANCE; GENE EXPRESSION; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; PERIPHERAL NERVOUS SYSTEM DISEASES; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84962441619     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.134213     Document Type: Article

References (22)

1. Van Den Neste E, Casasnovas O, André M, et al. Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013; 98(8): 1185-1195.
2. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009; 9(1): 15-27.
3. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res. 2011; 17(20): 6428-6436.
4. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363(19): 1812-1821.
5. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30(18): 2183-2189.
6. + hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012; 120(7): 1470-1472.
7. + lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013; 98(4): 611-614.
8. Zinzani PL, Viviani S, Anastasia A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica. 2013; 98(8): 1232-1236.
9. Monjanel H, Deville L, Ram-Wolff C, et al. Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients. Br J Haematol. 2014; 166(2): 306-308.
10. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4): 1244.
11. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5): 579-586.
12. Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012; 119(26): 6379-6381.
13. Garciaz S, Coso D, Peyrade F, et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Hematol Oncol. 2014; 32(4): 187-191.
14. Chen R, Palmer JM, Tsai N-C, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014; 20(11): 1864-1868.
15. Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015; 125(8): 1236-1243.
16. Dozzo M, Zaja F, Volpetti S, Sperotto A, Magli A, Fanin R. Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. Am J Hematol. 2015; 90(4): E73.
17. Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012; 120(3): 560-568.
18. Carlo-Stella C, Ricci F, Dalto S, et al. Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. Oncologist. 2015; 20(3): 323-328.
19. Theurich S, Malcher J, Wennhold K, et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stemcell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol. 2013; 31(5): e59-63.
20. Chen RW, Palmer J, Martin P, et al. Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. Blood. 2014; 124 (21): abst 501.
21. LaCasce A, Bociek RG, Matous J, et al. Brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma who are relapsed or refractory after frontline therapy. Blood. 2014; 124 (21): abst 293.
22. Michallet A-S, Guillermin Y, Deau B, et al. Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma. Haematologica. 2015; 100(7): e269-271.